54 results about "Sulindac" patented technology

The present invention provides compositions and methods for preventing the development of or reducing the growth of gastrointestinal tumors. The composition comprises polymeric microspheres encapsulating sulindac, IL-12 or both. These polymeric microspheres can be administered orally to individuals to reduce the growth of or prevent the development of gastrointestinal tumors.

The NSAID, sulindac and/or its metabolites and derivatives, in combination with hydrogen peroxide or another oxidizing agent, such as arsenic trioxide that generates reactive oxygen species (ROS), significantly enhances the killing of cancer cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against cancer cells. A skin cream has been developed and used to treat skin cancer and precancerous skin growths that effectively removes the lesions with no effect on surrounding normal skin.

The present invention provides a topical formulation containing NSAID, particularly diclofenac. The topical formulation is particularly useful for alleviating pain/inflammation associated with infection caused by herpes virus, especially herpes simplex virus (HSV) and varicella-zoster virus (VZV). Similar relief can be achieved where diclofenac is replaced with another non-steroidal anti-inflammatory drug (NSAID), which includes, without limitation, etodolac, ketorolac, bromfenac, diflunisal, ibuprofen, fenoprofen, ketoprofen, naproxen, suprofen, meclofenamate, mefenamic acid, piroxicam, meloxicam, indomethacin, sulindac, phenylbutazone, oxyphenbutazone, and tolmetin. The topical formulation is further characterized by its fast relief on pain and/or inflammation associated with infection caused by herpes virus, i.e., a complete relief in no more than seven (7) days after the application of the topical formulation on skins of patients.

The invention provides a preparation method of a chiral sulfoxide medicament though catalysis of asymmetric oxidation of sulfides compounds. A chiral complex formed by quadridentate nitrogen organic ligand and metal manganese compound as a catalyst and hydrogen peroxide as an oxidant are used for asymmetric catalytic oxidation of prochiral thioether compound, so as to obtain the corresponding chiral sulfoxide medicament compounds including S-omeprazole, S-lansoprazole, S-pantoprazole, S-rabeprazole, R-Modafinil and R-sulindac. The reaction has the advantages of cleaness, mild reaction conditions, high conversion rate and antipodal selectivity, and shows industrial prospects.

The invention discloses application of sulindac in preparation of a medicine for treating autism. The application of sulindac in preparation of the medicine for treating autism is characterized in that a VPA (Valproic Acid) autism animal model shows that sulindac is able to reduce abnormal behavior of an autistic, such as repeated mechanical behavior deficiency and human communication disorders; the primary culture neuron and VPA autism animal model verify the occurrence mechanism of autism as well as the functional mechanism of sulindac in treating autistic, and also prove that sulindac has oxidation resistance, and the oxidation resistance is related to down-regulating of the activity of a canonical Wnt signal channel. Therefore, sulindac is able to reduce the repeated mechanical behavior, abnormal behavior and human communication disorders of the autistic and can be used for preparing the medicine for treating autism.

The invention discloses a treatment method of landfill leachate. The method comprises the following steps: removing suspended matters and floating matters in the landfill leachate by a mechanical grille, and adding PAC (polyaluminium chloride) and PAM (polyacrylamide) into the leachate to perform coagulation sedimentation and ultrafiltration treatment to remove metals, SS (sulindac sulfides) and partial organic matters in the leachate and reduce the treatment load of a follow-up membrane biological fluidized bed unit; then enabling the leachate after treatment to enter the membrane biological fluidized bed, maintaining the relatively high sludge concentration in the membrane biological fluidized bed, and performing biological treatment to remove soluble COD (chemical oxygen demand), BOD (biochemical oxygen demand) and ammonia nitrogen in the leachate; and finally removing the organic matters and salts, which are difficult to degrade, by a reverse osmosis membrane so as to realize up-to-standard emission of outlet water. The treatment method disclosed by the invention has the advantages of strong ability of being suitable for changes in water quality, high impact-resistant load, short treatment period, high treatment efficiency, good effect on removing pollutants, high removal rate of the COD, BOD and ammonia nitrogen of above 97%, small occupied area, high degree of automation and low cost.

The NSAID, sulindac and/or its metabolites and derivatives, in combination with an agent that generates or induces reactive oxygen species (ROS), significantly enhances the killing of abnormal cells but does not affect normal cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against the abnormal cells.

The invention discloses a synthesis method and application of intermediates of a sulindac analogue, relating to intermediates of a sulindac analogue. The intermediates are 5-fluoro-2-metyl-3-indene ethyl acetate (5a) and 5-fluoro-2-metyl-3-indene acetic acid (5b). The synthesis method comprises the following steps of: subjecting 4-fluorobenzaldehyde as an initial raw material, propionic anhydride as a solvent and propionic anhydride to a perkin reaction to obtain 4-fluoro-2-metyl-methylcinnamic acid; catalyzing the 4-fluoro-2-metyl-methylcinnamic acid with palladium carbon with the palladium content of 5-20 percent and reducing in the hydrogen gas atmosphere to obtain 3-(4-fluorine phenyl)-2-methyl propionate; subjecting the 3-(4-fluorine phenyl)-2-methyl propionate to the intramolecilar friedel-crafts acyl browning reaction under the action of polyphosphoric acid under the heating condition to form 6-fluoro-2-methyl indene ketone; and subjecting the 6-fluoro-2-methyl indene ketone and halogenated acetate to reformatsky reaction under the action of the activated zinc powder to obtain a crude product and eliminating the crude product in an acid solution to obtain 5-fluoro-2-metyl-3-indene acetate. The intermediates can be used for preparing novel sulindac analogues with anticancer activity.

Derivatives of sulindac are provided along with-pharmaceutical compositions containing them and use for precancerous conditions and treating cancer. Derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.

The novel positively charged pro-drugs of aryl- and heteroarylacetic acids in the general formula(1) 'Structure 1' were designed and synthesized. The compounds of the general formula(1) 'Structure 1' indicated above can be prepared from functional derivatives of tolmetin, zomepirac, etodolac, amfenac, bromofenac, alclofenac, fenclofenac, acemetacin, indomethacin, sulindac, fentiazac, lonazolac, bendazac, 6MNA, ibufenac, and related compounds, (for example acid halides or mixed anhydrides), by reaction with suitable alcohols, thiols, or amines. The positively charged amino groups of these pro-drugs not only largely increases the solubility of the drugs, but also bonds to the negative charge on the phosphate head group of membranes and pushes the pro-drug into the cytosol. The results suggest that the pro-drugs diffuses through human skin 100 times faster than does tolmetin, zomepirac, etodolac, amfenac, bromofenac, alclofenac, fenclofenac, acemetacin, indomethacin, sulindac, fentiazac, lonazolac, bendazac, or related compounds. It takes 2-4 hours for tolmetin, zomepirac, etodolac, amfenac, bromofenac, alclofenac, fenclofenac, acemetacin, indomethacin, sulindac, fentiazac, lonazolac, bendazac, 6MNA, ibufenac, and related compounds to reach the peak plasma level when they are taken orally, but these prodrugs only took about 40-50 minutes to reach the peak plasma level when they are taken transdermally. In plasma, more than 90% of these pro-drugs can change back to the drug in a few minutes. The prodrugs can be used medicinally in treating any NSAIAs-treatable conditions in humans or animals. The prodrugs can be administered not only orally, but also transdermally for any kind of medical treatments and avoid most of the side effects of NSAIAs, most notably GI disturbances such as dyspepsia, gastroduodenal bleeding, gastric ulcerations, and gastritis.

The invention relates to the technical field of medicine composition and in particular relates to a method for preparing sulindac. The method comprises the following steps: mixing 5-fluorine-2-methyl-1-(4-methyl thiobenzene methylene)-3-indene acetic acid, a photosensitizer, an oxidant and a reaction solvent, and carrying out an oxidation reaction under an ultraviolet radiation condition, therebyobtaining sulindac, wherein the 5-fluorine-2-methyl-1-(4-methyl thiobenzene methylene)-3-indene acetic acid comprises an E-shaped isomer and a Z-shaped isomer. By adopting the method provided by the invention, the sulindac is prepared from the 5-fluorine-2-methyl-1-(4-methyl thiobenzene methylene)-3-indene acetic acid of the E-shaped isomer and the Z-shaped isomer as raw materials through the oxidation reaction directly, separation purification is avoided, and the operation is simple. Experiment results of the embodiment show that when the sulindac is prepared by using the method provided by the invention, the yield is up to 98.9%, the purity is greater than 99.5%, and the method has the advantages of being high in yield and good in purity.

The invention discloses a process for preparing sulindac comprising the steps of, condensating 4-fluorobenzyl chloride and diethyl methylmalonate at the presence of organic base, obtaining 2-(4-fluorobenzyl)-2-diethyl methylmalonate, hydrolyzing in aqueous alkali to obtain 2-(4-fluorobenzyl)-2-methyl malonic acid, carrying out decarboxylation directly under high temperature to obtain 3-(4-fluorophenyl)-2-methylpropanoic acid, chlorinating with sulfoxide acyl chloride, then using aluminium trichloride or waterless zinc chloride as catalyst, carrying out F-C acylation to obtain 6-fluoro-2-methylindanone, condensing with cyanocetic acid, hydrolyzing to obtain 5-fluoro-methyl-3-indenes acetic acid, then condensing with p-methylthiobenzaldehyde to obtain 5-fluoro-2-methyl-1-(4-methylthiobenzal)-3-indenes acetic acid, finally using organic acid as solvent, peracid or hydroperoxide as oxidation agent to obtain the sulindac.

The invention relates to a quantum dot immunochromatography detection card and method for detecting sulindac through a tertiary system competitive immunoassay process. The detection card comprises a substrate, a detection antigen release pad, a quantum dot probe release pad, a chromatography film and a water absorbing pad, the detection antigen release pad contains detection antigen formed by coupling of ovalbumin and naproxen, the quantum dot probe release pad comprises a quantum dot probe marked with anti-ovalbumin antibody, the chromatography film is provided with a detection line and a quality control line, the detection line fixes anti-naproxen antibody, and the quality control line fixes ovalbumin antigen. The detection antigen is dissolved in a detection system from the release pad,the detection antigen, detection antibody and marking antibody form a tertiary system immune compound, and fluorescent detection signals are generated. Under detection reference action of the qualitycontrol line, whether samples contain sulindac or not is judged according to fluorescent signals on the detection line, so that signal intensity and stability of detection are improved, and detectionsensitivity and quantification accuracy are improved.

Disclosed are non-steroidal analgesic and analgesic anti-inflammatory agents containing carboxyl including sodium, calcium, zinc, magnesium, N-n-octylgucamine, Arginine, Lycine or Trometamol salts of Loxoprofen, Ketoprofen, Pranoprofen, Tiaprofenic acid, Butibufen, Omolofen, epoxy indene acid, Lobuprofen, Clofenamic acid, Clonixin, Fenoprofen, Benorilate, Flurbiprofen, Alminoprofen, Bucloxic acid, Sulindac, Zidometacin, Acemetacin, Ketorolac, Risedronic acid, Sulindac, Lonaprofen, aspirin, Florfenicol, tiaprofenic acid, overall evaluation shows that trometamol salts are the best choice in terms of physicochemical properties, solvability, stability, local irritation, blood vessel irritation, and bioavailability for oral administration.

Described herein are kits, compositions, and combination therapies comprising sulindac for use in the treatment of fragile X syndrome (FXS).

The invention provides compositions comprising sulindac, R-epimer sulindac, S-epimer sulindac, derivatives, metabolites, and structural analogs thereof which protect normal cells against damage caused by solar rays, oxidative damage, environmental factors, diseases and organisms.

Provided herein are fixed-dose combination formulations of a pharmaceutically effective amount of eflornithine together with a pharmaceutically effective amount of sulindac. Also provided are methods of use and of methods of manufacture of these formulations.